Humira (adalimumab) / AbbVie 
Welcome,         Profile    Billing    Logout  
 200 Diseases   191 Trials   191 Trials   19827 News 


«12...169170171172173174175176177178179...203204»
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    New P4 trial, Head-to-Head:  Dose Tapering Study of Adalimumab in Psoriasis (clinicaltrials.gov) -  Jul 23, 2019   
    P4,  N=160, Not yet recruiting, 
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Clinical, Journal:  Adalimumab use in patients with psoriasis and hepatitis B: a case series. (Pubmed Central) -  Jul 21, 2019   
    The underlying mechanisms are unclear, but data suggest that formation of anti-drug antibodies leads to sub-therapeutic drug levels and thereby loss of efficacy (3). Tumor necrosis factor (TNF) inhibitors neutralize the biologic activity of TNF-alpha, a key cytokine involved in both the pathogenesis of psoriasis and host immune response in suppressing microbial proliferation.(1) It is well known that chronic hepatitis B virus (HBV) carriers are at high risk of HBV reactivation when using immunosuppressive medications, chemotherapy, and TNF inhibitors.(2-4) However, HBV reactivation in patients with resolved HBV infection using TNF inhibitors is exceedingly rare, and to our knowledge has not been reported in the psoriasis literature.
  • ||||||||||  Enbrel (etanercept) / Takeda, Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, Dermira, UCB
    Clinical, Journal:  Effects of a 15-month anti-TNF-α treatment on plasma levels of glycosaminoglycans in women with rheumatoid arthritis. (Pubmed Central) -  Jul 19, 2019   
    Tumor necrosis factor (TNF) inhibitors neutralize the biologic activity of TNF-alpha, a key cytokine involved in both the pathogenesis of psoriasis and host immune response in suppressing microbial proliferation.(1) It is well known that chronic hepatitis B virus (HBV) carriers are at high risk of HBV reactivation when using immunosuppressive medications, chemotherapy, and TNF inhibitors.(2-4) However, HBV reactivation in patients with resolved HBV infection using TNF inhibitors is exceedingly rare, and to our knowledge has not been reported in the psoriasis literature. Our results suggest that anti-TNF-α therapy has a beneficial effect on extracellular matrix remodeling in the course of RA.
  • ||||||||||  Remicade (infliximab) / Mitsubishi Tanabe, J&J, Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
    Clinical, Journal:  Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease. (Pubmed Central) -  Jul 19, 2019   
    Expert opinion: Although there is a consensus across studies that higher anti-TNF trough levels are associated with a better clinical outcome, and that early anti-TNF serum measurements could be predictive of long-term response, it is still not clear what the best predictive time of sampling is and what the ideal target drug plasma concentration to achieve. Indeed, there are a number of published studies, particularly in pediatric cohorts, limited by the population size analysed and more prospective large studies are needed to examine the value of these predictive markers.
  • ||||||||||  Review, Journal:  Therapeutic drug monitoring of biologics in psoriasis. (Pubmed Central) -  Jul 18, 2019   
    We also propose a treatment algorithm for the practical application of TDM depending on drug trough concentrations, presence/absence of anti-drug antibodies and clinical response of patients. The practice of TDM is recommended in routine clinical practice where possible.
  • ||||||||||  Humira (adalimumab) / Eisai, AbbVie
    Journal, Heterogeneity:  Comprehensive characterisation of the heterogeneity of adalimumab via charge variant analysis hyphenated on-line to native high resolution Orbitrap mass spectrometry. (Pubmed Central) -  Jul 17, 2019   
    By combining molecular mass and retention time information, we were able to identify multiple modifications on adalimumab, including lysine truncation, glycation, deamidation, succinimde formation, isomerisation, N-terminal aspartic acid loss or C-terminal proline amidation and fragmentation along with the N-glycan distribution of each of these identified proteoforms. Host cell protein (HCP) analysis was performed using liquid chromatography-mass spectrometry that verified the presence of the protease Cathepsin L. Based on the presence of trace HCPs with catalytic activity, it can be questioned if fragmentation is solely driven by spontaneous hydrolysis or possibly also by enzymatic degradation.
  • ||||||||||  Biomarker, Journal:  Management of inflammatory bowel disease. (Pubmed Central) -  Jul 13, 2019   
    Drug treatments for IBD now include five biological drugs listed by the Pharmaceutical Benefits Scheme: adalimumab, infliximab, golimumab, vedolizumab and ustekinumab. Such developments offer the possibility for improved disease control in selected patients.
  • ||||||||||  Entyvio (vedolizumab) / Takeda
    Trial completion date:  Entyvio PASS: Entyvio (Vedolizumab) Long Term Safety Study (clinicaltrials.gov) -  Jul 12, 2019   
    P=N/A,  N=5000, Recruiting, 
    This study provides preliminary evidence that a phone call intervention, aiming to improve the overall patient experience with adalimumab treatment, may increase the likelihood of HBI remission in patients taking adalimumab to manage CD. Trial completion date: Jun 2022 --> Jul 2021